Zamifenacin (UK-76, 654), a potent gut M3 selective muscarinic antagonist, reduces colonic motor activity in patients with irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 3, 1997, Pages 561-568

  Houghton, L A ^a   Rogers, J ^b   Whorwell, P J ^a   Campbell, F C ^c   Williams, N S ^b   Goka, J ^d  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c NINEWELLS HOSPITAL   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; ZAMIFENACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON MOTILITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; IRRITABLE COLON; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0030854609     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00189.x     Document Type: Article

References (47)

1. Thompson DG, Laidlow JM, Wingate DL. Abnormal small bowel motility demonstrated by radiotelemetry in a patient with irritable colon. Lancet 1979; ii: 1321-3.
2. Kumar D, Wingate DL. The irritable bowel syndrome: a paroxysmal motor disorder. Lancet 1985; ii: 973-7.
3. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-93.
4. Wangel AG, Deller DJ. Intestinal motility in man. III. Mechanisms of constipation and diarrhoea with particular reference to the irritable colon syndrome. Gastroenterology 1965; 48: 69-84.
5. Connell AM, Avery Jones F, Rowlands EN. Motility of the pelvic colon. IV. Abdominal pain associated with colonic hypermotility after meals. Gut 1965; 6: 105-12.
6. Sullivan MA, Cohen S, Snape WJ. Colonic myoelectrical activity in irritable bowel syndrome: effect of eating and anticholinergics. New Engl J Med 1978; 298: 878-83.
7. Narducci F, Bassotti G, Granata MT, et al. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide. Dig Dis Sci 1986; 31: 241-6.
8. Holdstock DJ, Misiewicz JJ, Waller SL. Observations on the mechanism of abdominal pain. Gut 1969; 10: 19-31.
9. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-32.
10. Whitehead WE, Holtkotter B, Enck P, et al. Tolerance for rectosigmoid distension in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
11. Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 458-62.
12. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhoea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25: 404-13.
13. Prior A, Sun W-M, Read NW. Irritable bowel syndrome: differences between patients who show rectal sensitivity and those who do not. Eur J Gastroenterol Hepatol 1993; 5: 343-9.
14. Costantini M, Sturniolo GC, Zaninotto G, et al. Altered esophageal pain threshold in irritable bowel syndrome. Dig Dis Sci 1993; 38: 206-12.
15. Francis CY, Houghton LA, Whorwell PJ, Morris J, Bradbury J. Enhanced sensitivity of the whole gut in patients with irritable bowel syndrome. Gastroenterology 1995; 108: 601.
16. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91.
17. Snape WJ, Carlson GM, Matarazzo SA, et al. Evidence that abnormal myoelectrical activity produces colonie motor dysfunction in irritable bowel syndrome. Gastroenterology 1977; 72: 383-7.
18. Welgan P, Meshkinpour H, Beeler M. Effect of anger in colon motor and myoelectric activity in irritable bowel syndrome. Gastroenterology 1988; 94: 1150-6.
19. Whorwell PJ, Houghton LA, Taylor EE, Maxton DG. Physiological effects of emotion: assessment via hypnosis. Lancet 1992; 340: 69-72.
20. Narducci F, Snape WJ, Battle WM, London RL, Cohen S. Increased colonic motility during exposure to a stressful situation. Dig Dis Sci 1985: 30: 40-4.
21. Houghton LA, Cooper P, Jackson NA, Whorwell PJ. Visceral sensation and emotion: a study using hypnosis. Gastroenterology 1995; 108: 3470(Abstract).
22. Greenbaum D, Abitz L, VanEgeren L, Mayle J, Greenbaum R. Irritable bowel syndrome prevalence, rectosigmoid motility and psychometrics in symptomatic subjects not seeking physicians. Gastroenterology 1983; 84: A1174(Abstract).
23. Drossman DA, McKee DC, Sandler RS, et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and non-patients with irritable bowel syndrome. Gastroenterology 1988; 95: 701-8.
24. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Schuster MM. Symptoms of psychological distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology 1988; 95: 709-14.
25. Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 1994; 344: 39-40.
26. Lancaster-Smith MJ, Prout BJ, Pinto T, Anderson JA, Schiff AA. Influence of drug treatment on the irritable bowel syndrome and its interaction with psychoneurotic morbidity. Acta Psychiatr Scand 1982; 66: 33-41.
27. Myren J, Groth H, Larssen SE, Larsen S. The effect of trimipramine in patients with irritable bowel syndrome: a double blind study. Scand J Gastroenterol 1982; 17: 871-5.
28. Heefner JD, Wilder RM, Wilson ID. Irritable colon and depression. Psychosomatics 1978; 19: 540-7.
29. Steinhart MJ, Wong PY, Zarr ML. Therapeutic usefulness of amitriptyline in spastic colon syndrome. Int J Psychiatry Med 1981-2; 11: 45-57.
30. Dotevall G, Groll E. Controlled clinical trial of mepiprazole in irritable bowel syndrome. Br Med J 1974; 4: 16-8.
31. Kruis W, Weinsierl M, Schussler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with irritable bowel syndrome. Digestion 1986; 34: 196-201.
32. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent meberverine on the human colon. Br Med J 1965; 2: 848-51.
33. Baume P. Mebervine, an effective agent in irritable bowel syndrome. Aust NZ J Med 1972; 2: 34-6.
34. Tasman-Jones C. Mebeverine in patients with irritable colon syndrome: double blind study. NZ Med J 1973; 77: 232-5.
35. Berthelot J, Centonze M. Etude controlee en double aveugle Duspatalin (Mebeverine) contre placebo, dans le traitement du colon irritable. Gaz Med Fr 1981; 88: 2341-3.
36. Piai G, Mazzacca G. Prifinium bromide in the treatment of the irritable colon syndrome. Gastroenterology 1979; 77: 500-2.
37. Rees WDW, Evans BK, Rhodes J. Treating irritable bowel syndrome with peppermint oil. Br Med J 1979; 2: 835-6.
38. Talley NJ. 5-Hydroxytrptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1992; 6: 273-89.
39. Costall B, Naylor RJ. 5-Hydroxytryptamine new receptors and novel drugs for gastrointestinal motor disorders. Scand J Gastroenterol 1990; 25: 769-87.
40. Steadman C, Talley NJ, Phillips SF, Van Dyke C. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhoea-predominant IBS: a pilot study. Mayo Clin Proc 1992; 67: 732-8.
41. 3 antagonists: a role in irritable bowel syndrome and non-ulcer dyspepsia. Gut 1991; 32: A1228(Abstract).
42. 3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80.
43. 3 antagonism does not modify visceral sensation or compliance in healthy subjects. Gastroenterology 1993; 104: A512(Abstract).
44. 3 receptor antagonist on perception of gastric distension and gastric compliance in healthy man. Gastroenterology 1993; 104: A603(Abstract).
45. Switz DM. What the gastroenterologist does all day. Gastroenterology 1976; 70: 1048-50.
46. Ferguson A, Sircus W, Eastwood MA. Frequency of functional gastrointestinal disorders. Lancet 1977; ii: 613-4.
47. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology outpatients. Lancet 1983; i: 632-4.